← 返回

从代谢副产物到免疫调节剂:乳酸在肿瘤免疫逃逸中的作用

英文原题:From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape.

查看英文原题

From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape.

PubMed 2024/11/25(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

乳酸是肿瘤微环境中的关键代谢副产物,因其在免疫逃逸机制中的作用而备受关注。肿瘤细胞通过Warburg效应引起的异常糖酵解产生并释放大量乳酸进入肿瘤微环境,导致pH下降。乳酸水平升高会深刻抑制肿瘤部位巨噬细胞和NK 细胞等免疫效应细胞的增殖能力、细胞毒性功能和迁移能力。

此外,乳酸还能调节免疫细胞表面分子的表达,干扰其对肿瘤细胞的识别和攻击,并调控促进调节性T细胞等免疫抑制细胞扩增和功能增强的信号通路,从而在肿瘤微环境中促进免疫耐受。当前研究正在积极探索靶向乳酸代谢以改善肿瘤免疫逃逸的策略。正在研究的关键方法包括抑制乳酸生成中关键酶的活性以减少其合成,或阻断乳酸转运体以改变细胞内和细胞外乳酸分布。这些方法有望与现有的免疫疗法如免疫检查点抑制剂和CAR-T 细胞疗法联合使用,以增强免疫系统消除肿瘤细胞的能力。这可能为临床癌症治疗中的新型联合治疗策略铺平道路,有效克服肿瘤免疫逃逸现象,并最终提高整体治疗效果。

展开英文摘要原文

Lactic acid, a key metabolic byproduct within the tumor microenvironment, has garnered significant attention for its role in immune evasion mechanisms. Tumor cells produce and release large amounts of lactic acid into the tumor microenvironment through aberrant glycolysis via the Warburg effect, leading to a drop in pH. Elevated lactic acid levels profoundly suppress proliferation capacity, cytotoxic functions, and migratory abilities of immune effector cells such as macrophages and natural killer cells at the tumor site.

Moreover, lactic acid can modulate the expression of surface molecules on immune cells, interfering with their recognition and attack of tumor cells, and it regulates signaling pathways that promote the expansion and enhanced function of immunosuppressive cells like regulatory T cells, thereby fostering immune tolerance within the tumor microenvironment. Current research is actively exploring strategies targeting lactic acid metabolism to ameliorate tumor immune evasion.

Key approaches under investigation include inhibiting the activity of critical enzymes in lactic acid production to reduce its synthesis or blocking lactate transporters to alter intracellular and extracellular lactate distribution.

These methods hold promise when combined with existing immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies to enhance the immune system's ability to eliminate tumor cells. This could pave the way for novel combinatorial treatment strategies in clinical cancer therapy, effectively overcoming tumor immune evasion phenomena, and ultimately improving overall treatment efficacy.

论文信息

作者
Jiang M、Wang Y、Zhao X、Yu J
单位
School of Clinical Medicine, Shandong Second Medical University, Weifang, China.China
文献类型
综述
期刊
Frontiers in immunology2024
原文标识
PubMed 39654883 · DOI 10.3389/fimmu.2024.1492050